Financial Results for the Fiscal Year
Ended March 31, 2021 (FY2020)

from the beginning

Financial Results for the Fiscal Year Ended March 31, 2021 (FY2020)

• Safe Harbor for Forward-Looking Statements and Use of Document

• Highlights

• P&L Results

• Adjusted Operating Profit Variance Analysis (FY20 Q4 YTD)

• Adjusted Operating Profit Variance Analysis (FY20 Q4)

• Revenue by Region

• C&V

• GH

• TBCT

• Major Topics in FY20 Q4

• FY21 Guidance

• FY21 Guidance: Profit Variance Analysis (for 670 B JPY Revenue Scenario)

• FY21 Guidance by Company (for 670 B JPY Revenue Scenario)

• Dividend Proposal

Reference

• FY20 New Product Pipeline

• FY21 New Product Pipeline

• Revenue by Segment and Region

• Operating Expenses

• Quarterly Results

• Adjusted Operating Profit: Adjustments

• CAPEX, Depreciation and R&D Expenses

• Cash Flows (FY20 Q4 YTD)

• Cash Flows (FY20 Q4)

• FY21 Guidance: Profit Variance Analysis (for 670 B JPY Revenue Scenario)

• Details of FY20 FX Impact (Flow and Stock)

• Foreign Exchange Sensitivity

@

Diabetes Management (DM Business) Strategic Direction

• Safe Harbor for Forward-Looking StatementsandUse of Document

• Disease-oriented approach fighting four major diseases that affect society

• DM business: Still small and Japan-focused

• Leverage rich product lineup to deploy overall solutions in the new mid-to long-term growth strategy

• Evolve DM success factors using digital and AI

• DM market: Enormous medical device segment

• DM market: 7%+ growth in primary products. Products have regional characteristics

• World-leading product lineup through internal R&D and collaboration

• Insulin pump: Achieves same precision as tube products

• Global deployment addressing regional characteristics

• Accelerate personalization with solution offerings from outside collaboration

• Target sales revenue approaching 50 B JPY in 10 years

@